|D012128||Respiratory Distress Syndrome, Adult NIH||0.07|
There is one clinical trial.
Experimental intervention: Insertion of Extracorporal Membrane Oxygenation (ECMO) within 24 hours of referral to an Intensive Care Unit. Control intervention: Insertion of Extracorporal Membrane Oxygenation (ECMO) as rescue therapy following failure of conventional therapy for ARDS. This conventional therapy will be standardized to reduce bias. Duration of intervention per patient: varies, depending on severity of pulmonary compromise Follow-up per patient: Until hospital discharge Accompanying measures: Serum Samples and bronchoscopy samples of patients included into the trial for secondary analysis of inflammatory parameters and potential biomarkers
Description: survival in 28-day follow-up period (28 day all cause mortality)Measure: 28 day all cause mortality Time: 28 Days
Description: 90 day all cause mortalityMeasure: 90 day all cause mortality Time: 90 days
Description: Sepsis-related organ failure assessment score at day 1-14, 28 and 90 daysMeasure: Sepsis-related organ failure assessment score at day 1-14, 28 and 90 days Time: day 1-14, 28 and 90
Description: duration of mechanical ventilation supportMeasure: duration of mechanical ventilation support Time: 28 days
Description: Number of patients with Ventilator Associated PneumoniaMeasure: Ventilator Associated Pneumonia Time: 28 days
Description: number of blood transfusion unitsMeasure: Bleeding complications Time: 28 das
Description: Days on real replacement therapyMeasure: Acute Renal Failure Time: 28 days
Description: Discharge to (home, skilled nursing facility, rehabilitation)Measure: Discharge Location Time: 90 days
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports